Pharmaron Beijing（17Q1）株式概要ファーマロン北京有限公司は、その子会社とともに、北米、欧州、日本、中国本土、および国際的なライフサイエンス業界に医薬品の研究開発および製造サービスを提供しています。 詳細17Q1 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長4/6過去の実績2/6財務の健全性5/6配当金0/6報酬収益は年間22.56%増加すると予測されています リスク分析German市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見る17Q1 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW475,857 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA475,857 investors already sharing narrativesYour Fair Value€Current Price€3.2057.6% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture029b2016201920222025202620282031Revenue CN¥29.0bEarnings CN¥3.4bAdvancedSet Fair ValueView all narrativesPharmaron Beijing Co., Ltd. 競合他社SartoriusSymbol: XTRA:SRT3Market cap: €14.8bSCHOTT Pharma KGaASymbol: XTRA:1SXPMarket cap: €3.3bBio-TechneSymbol: NasdaqGS:TECHMarket cap: US$11.3bEurofins ScientificSymbol: ENXTPA:ERFMarket cap: €12.2b価格と性能株価の高値、安値、推移の概要Pharmaron Beijing過去の株価現在の株価CN¥3.2052週高値CN¥3.3252週安値CN¥1.60ベータ0.621ヶ月の変化25.00%3ヶ月変化63.27%1年変化32.23%3年間の変化65.80%5年間の変化-55.83%IPOからの変化46.37%最新ニュースお知らせ • Jun 30Pharmaron Beijing Co., Ltd. to Report First Half, 2026 Results on Aug 21, 2026Pharmaron Beijing Co., Ltd. announced that they will report first half, 2026 results on Aug 21, 2026お知らせ • Jun 16Pharmaron Beijing Co., Ltd. Approves Cash Dividend for 2025Pharmaron Beijing Co., Ltd. at its AGM held on June 12, 2026, approved cash dividend of CNY 2.00000000 per 10 shares (tax included) for 2025.お知らせ • May 22Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026, at 13:30 China Standard Time. Location: juhui hall, 5/floor, block b, zhaolin plaza, no. 19 ronghua middle road, beijing economic & technological development area, daxing district, beijing., Chinaお知らせ • Apr 30Pharmaron Beijing Co., Ltd. Approves Changes in the Company's Accounting PoliciesThe board of directors of Pharmaron Beijing Co., Ltd. that the Board has resolved and approved the proposed changes in the Company's accounting policies. This announcement is made pursuant to the requirements of Rule 13.09(2) of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571). On April 28, 2026, the audit committee of the Board (the "Audit Committee") reviewed and approved the Changes in Accounting Policies, the details of which are as follows: Overview of Changes in Accounting Policies (i) Nature, reasons and effective date of the Changes in Accounting Policies In December, 2025, the Ministry of Finance issued the Notice on the Issuance of Interpretation No. 19 of Accounting Standards for Business Enterprises (Cai Kuai [2025] No. 32) (hereinafter referred to as "Interpretation No. 19"), which stipulates the accounting treatments regarding (i) accounting treatment of indemnification assets in business combinations under non-common control, (ii) accounting treatment of disposing of capital reserve related to the acquisition of subsidiaries through business combinations under common control, (iii) derecognition of financial liabilities settled through electronic payment systems, (iv) assessment of contractual cash flow characteristics of financial assets and related disclosures, and (v) disclosures of equity instruments designated as measured at fair value through other comprehensive income. The Interpretation No. 19 shall take effect from January 1, 2026. In accordance with the Interpretation No. 19, the Company has adopted the above accounting standards for business enterprises and the related accounting policies commencing from the effective date specified therein. These Changes in Accounting Policies are made in accordance with the requirements of the unified national accounting system. (ii) Accounting policies adopted prior to the Changes in Accounting Policies Prior to the Changes in Accounting Policies, the Company adopted the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations issued by the Ministry of Finance. (iii) Accounting policies adopted after the Changes in Accounting Policies After the Changes in Accounting Policies, the Company will adopt the requirements of Interpretation No. 19. The unchanged remaining parts will continue to follow the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, the Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations previously issued by the Ministry of Finance. II. Impacts of Changes in Accounting Policies on the Company These Changes in Accounting Policies are made by the Company in accordance with the relevant regulations and requirements of the Ministry of Finance, and are in compliance with relevant laws and regulations. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years, will have no material effect on the Company's financial position, operating results or cash flows, and do not prejudice the interests of the Company and all of its shareholders. The Change in Accounting Policies is a modification under the China Accounting Standards, and will not have any impact on the Company's audited consolidated financial statements prepared in accordance with IFRS Accounting Standards (which include all International Financial Reporting Standards, International Accounting Standards and Interpretations) as issued by the International Accounting Standards Board. III. Opinion of the Audit Committee of the Board The Audit Committee is of the opinion that the Changes in Accounting Policies are made by the Company in compliance with the requirements of the relevant documents issued by the Ministry of Finance and constitute changes in accounting policies as required by the unified national accounting system. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years and do not prejudice the interests of the Company and all of its shareholders. The Audit Committee unanimously approved the Changes in Accounting Policies. In accordance with the Rules Governing the Listing of Stocks on the ChiNext Board of the Shenzhen Stock Exchange and other applicable laws, regulations and departmental rules, the Changes in Accounting Policies are not required to be submitted to the Board or the 2025 AGM for approval.お知らせ • Apr 29Pharmaron Beijing Co., Ltd. Announces Board ResignationsPharmaron Beijing Co., Ltd. announced that Mr. LI Jiaqing and Mr. YU Jian will not stand for re-election of the fourth session of the Board. Each of Mr. LI Jiaqing and Mr. YU Jian has confirmed that he has no disagreement with the Board and there is no matter that need to be brought to the attention of the Shareholders with regard to his resignation. As at the date of this announcement, neither Mr. LI Jiaqing nor Mr. YU Jian has any interest in the shares of the Company within the meaning of Part XV of the SFO nor any other matter which needs to be brought to the attention of the Shareholders. The Board would like to take this opportunity to express its appreciation and gratitude to Mr. LI Jiaqing and Mr. YU Jian for their valuable contribution made to the Company during their respective term of service.お知らせ • Mar 31Pharmaron Beijing Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026最新情報をもっと見るRecent updatesお知らせ • Jun 30Pharmaron Beijing Co., Ltd. to Report First Half, 2026 Results on Aug 21, 2026Pharmaron Beijing Co., Ltd. announced that they will report first half, 2026 results on Aug 21, 2026お知らせ • Jun 16Pharmaron Beijing Co., Ltd. Approves Cash Dividend for 2025Pharmaron Beijing Co., Ltd. at its AGM held on June 12, 2026, approved cash dividend of CNY 2.00000000 per 10 shares (tax included) for 2025.お知らせ • May 22Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026, at 13:30 China Standard Time. Location: juhui hall, 5/floor, block b, zhaolin plaza, no. 19 ronghua middle road, beijing economic & technological development area, daxing district, beijing., Chinaお知らせ • Apr 30Pharmaron Beijing Co., Ltd. Approves Changes in the Company's Accounting PoliciesThe board of directors of Pharmaron Beijing Co., Ltd. that the Board has resolved and approved the proposed changes in the Company's accounting policies. This announcement is made pursuant to the requirements of Rule 13.09(2) of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571). On April 28, 2026, the audit committee of the Board (the "Audit Committee") reviewed and approved the Changes in Accounting Policies, the details of which are as follows: Overview of Changes in Accounting Policies (i) Nature, reasons and effective date of the Changes in Accounting Policies In December, 2025, the Ministry of Finance issued the Notice on the Issuance of Interpretation No. 19 of Accounting Standards for Business Enterprises (Cai Kuai [2025] No. 32) (hereinafter referred to as "Interpretation No. 19"), which stipulates the accounting treatments regarding (i) accounting treatment of indemnification assets in business combinations under non-common control, (ii) accounting treatment of disposing of capital reserve related to the acquisition of subsidiaries through business combinations under common control, (iii) derecognition of financial liabilities settled through electronic payment systems, (iv) assessment of contractual cash flow characteristics of financial assets and related disclosures, and (v) disclosures of equity instruments designated as measured at fair value through other comprehensive income. The Interpretation No. 19 shall take effect from January 1, 2026. In accordance with the Interpretation No. 19, the Company has adopted the above accounting standards for business enterprises and the related accounting policies commencing from the effective date specified therein. These Changes in Accounting Policies are made in accordance with the requirements of the unified national accounting system. (ii) Accounting policies adopted prior to the Changes in Accounting Policies Prior to the Changes in Accounting Policies, the Company adopted the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations issued by the Ministry of Finance. (iii) Accounting policies adopted after the Changes in Accounting Policies After the Changes in Accounting Policies, the Company will adopt the requirements of Interpretation No. 19. The unchanged remaining parts will continue to follow the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, the Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations previously issued by the Ministry of Finance. II. Impacts of Changes in Accounting Policies on the Company These Changes in Accounting Policies are made by the Company in accordance with the relevant regulations and requirements of the Ministry of Finance, and are in compliance with relevant laws and regulations. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years, will have no material effect on the Company's financial position, operating results or cash flows, and do not prejudice the interests of the Company and all of its shareholders. The Change in Accounting Policies is a modification under the China Accounting Standards, and will not have any impact on the Company's audited consolidated financial statements prepared in accordance with IFRS Accounting Standards (which include all International Financial Reporting Standards, International Accounting Standards and Interpretations) as issued by the International Accounting Standards Board. III. Opinion of the Audit Committee of the Board The Audit Committee is of the opinion that the Changes in Accounting Policies are made by the Company in compliance with the requirements of the relevant documents issued by the Ministry of Finance and constitute changes in accounting policies as required by the unified national accounting system. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years and do not prejudice the interests of the Company and all of its shareholders. The Audit Committee unanimously approved the Changes in Accounting Policies. In accordance with the Rules Governing the Listing of Stocks on the ChiNext Board of the Shenzhen Stock Exchange and other applicable laws, regulations and departmental rules, the Changes in Accounting Policies are not required to be submitted to the Board or the 2025 AGM for approval.お知らせ • Apr 29Pharmaron Beijing Co., Ltd. Announces Board ResignationsPharmaron Beijing Co., Ltd. announced that Mr. LI Jiaqing and Mr. YU Jian will not stand for re-election of the fourth session of the Board. Each of Mr. LI Jiaqing and Mr. YU Jian has confirmed that he has no disagreement with the Board and there is no matter that need to be brought to the attention of the Shareholders with regard to his resignation. As at the date of this announcement, neither Mr. LI Jiaqing nor Mr. YU Jian has any interest in the shares of the Company within the meaning of Part XV of the SFO nor any other matter which needs to be brought to the attention of the Shareholders. The Board would like to take this opportunity to express its appreciation and gratitude to Mr. LI Jiaqing and Mr. YU Jian for their valuable contribution made to the Company during their respective term of service.お知らせ • Mar 31Pharmaron Beijing Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026お知らせ • Jan 22Pharmaron Beijing Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.333618 billion.Pharmaron Beijing Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.333618 billion. Security Name: H shares Security Type: Common Stock Securities Offered: 58,440,762 Price\Range: HKD 22.82 Transaction Features: Subsequent Direct Listingお知らせ • Jan 15Pharmaron Beijing Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 1.333618 billion.Pharmaron Beijing Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 1.333618 billion. Security Name: H shares Security Type: Common Stock Securities Offered: 58,440,762 Price\Range: HKD 22.82 Transaction Features: Subsequent Direct Listingお知らせ • Jan 14Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2025Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2025. For the period, the company expects the revenue in the range of RMB 13,871.6256 million to RMB 14,239.8989 million, growth compared with the same period of last year is 13% - 16%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,614.0157 million to RMB 1,685.7498 million, decrease compared with the same period of last year of 6% to 10%. Basic earnings per share is expected to be in the range of RMB 0.0.9160 to RMB 0.9567.お知らせ • Dec 31Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026お知らせ • Oct 29Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into a definitive Share Purchase Agreement to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd.Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into a definitive Share Purchase Agreement to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd. on October 28, 2025. With this transaction, it will further enhance its service capabilities in protein science, biological assaying and compound screening, protein crystallization and structure analysis and structure-based drug design. The transaction is expected to close upon the satisfaction of customary closing conditions.お知らせ • Sep 30Pharmaron Beijing Co., Ltd. to Report Q3, 2025 Results on Oct 29, 2025Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025お知らせ • Jul 02Pharmaron Beijing Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025Pharmaron Beijing Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025お知らせ • Jun 20Pharmaron Beijing Co., Ltd. Approves Final Ordinary Dividend for Year Ended December 31, 2024, Payment Date Is 06 August 2025Pharmaron Beijing Co., Ltd. approved final ordinary dividend in cash for the year ended December 31, 2024 of RMB 2 per 10 share. Ex-dividend date is 04 July 2025 . Record date is 14 July 2025. Payment date is 06 August 2025. Date of shareholders' approval is 20 June 2025.お知らせ • May 29Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 20, 2025Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 20, 2025, at 13:30 China Standard Time. Location: no. 1 meeting room,4th floor, grand skylight international hotel beijing, building 10, avic plaza, no. 15 ronghua south road, yizhuang economic and technological development, zone, daxing Chinaお知らせ • Apr 28Pharmaron Beijing Co., Ltd. Announces Resignation of Hu Baifeng as Non-Executive Director and A Member of the Strategy CommitteePharmaron Beijing Co., Ltd. announced that Mr. Hu Baifeng (Mr. Hu) has tendered a voluntary resignation from his position as a non-executive Director of the Company and a member of the strategy committee of the Board (the Strategy Committee). Following Mr. Hu's resignation, he has voluntarily agreed to continue to perform his duties as a non-executive Director and a member of the Strategy Committee until the proposed election of the new non-executive Director is resolved by the shareholders of the Company (the Shareholders) at the upcoming annual general meeting of the Company for the year 2024 (the 2024 AGM).お知らせ • Mar 31Pharmaron Beijing Co., Ltd. to Report Q1, 2025 Results on Apr 28, 2025Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2025 results on Apr 28, 2025お知らせ • Mar 26Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2024Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2024.お知らせ • Dec 31Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2024 Results on Mar 27, 2025Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2024 results on Mar 27, 2025お知らせ • Sep 30Pharmaron Beijing Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024お知らせ • Jun 29Pharmaron Beijing Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Pharmaron Beijing Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024お知らせ • Jun 22Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million and with potential for an additional milestone payment. on May 16, 2024. The transaction is subject to antitrust clearance and other customary closing conditions. The transaction is expected to close mid-year 2024. Centerview Partners LLC served as exclusive financial advisor, and Goodwin Procter as legal counsel to Proteologix on the transaction. The transaction has been approved by Pharmaron Beijing Co., Ltd's board.As of year ended 2023, Proteologix, Inc reported total assets of $31.04 million, total common equity of $30.73 million, EBIT of $5.74 million and net income of $5.74 million. Janet Xiao of Morrison & Foerster LLP acted as legal advisor to Proteologix, Inc.Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders on June 21, 2024.お知らせ • Jun 21Pharmaron Beijing Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable June 27, 2024Pharmaron Beijing Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 2.00000000 on A shares for the year 2023. Record date is June 26, 2024. Ex-date is June 27, 2023. Payment date is June 27, 2024.お知らせ • Jun 08Pharmaron Beijing Co., Ltd. Approves Final Dividend for the Financial Year Ended December 31, 2023, Payable on July 26, 2024Pharmaron Beijing Co., Ltd. approved final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023. Ex-dividend date is on 27 June 2024. Record date is on 08 July 2024. Payment date is on 26 July 2024. Date of shareholders' approval is on 6 June 2024.お知らせ • May 16Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024, at 13:30 China Standard Time. Location: paris hall, 3/f, pullman beijing south, no. 12 ronghua south road, beijing economic and technological development, area, daxing district, beijing Chinaお知らせ • Apr 26+ 1 more updatePharmaron Beijing Co., Ltd. (SZSE:300759) announces an Equity Buyback for CNY 300 million worth of its shares.Pharmaron Beijing Co., Ltd. (SZSE:300759) announces a share repurchase program. Under the program, the company will repurchase up to CNY 300 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 31 per share. The A Shares repurchased will all be cancelled and the Company’s registered capital will be reduced accordingly. The purpose of the program is to enhance investor’s confidence, and comprehensively taking into account the Company’s financial conditions, future development and reasonable valuation levels. The program will be funded out of the company's own funds. The program will be valid till 3 months.お知らせ • Mar 30Pharmaron Beijing Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024お知らせ • Mar 27Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023.お知らせ • Jan 29Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2023. For the period, the company expects the revenue in the range of RMB 11,395.5799 million to RMB 11,703.5685 million. Growth compared with the same period of last year is 11% - 14%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,567.0488 million to RMB 1,635.7790 million. Growth compared with the same period of last year of 14% to 19%. Basic earnings per share is expected to be in the range of RMB 0.8841 to 0.9229.お知らせ • Dec 29Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2023 results on Mar 28, 2024お知らせ • Jul 23Pharmaron Beijing Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 27, 2023Pharmaron Beijing Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 26, 2023. Ex-date is July 27, 2023. Payment date is July 27, 2023.お知らせ • Jun 27Pharmaron Beijing Co., Ltd. Approves Cash Dividend for 2022Pharmaron Beijing Co., Ltd. approved Cash dividend/10 shares (tax included) of CNY 3.00000000 for 2022 at the Class Meeting of Holders of Domestic Shares of 2023 held on June 21, 2023.お知らせ • May 26+ 1 more updatePharmaron Beijing Co., Ltd., Annual General Meeting, Jun 21, 2023Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 21, 2023, at 13:30 China Standard Time. Location: Juyuan Hall, 5/F, Block A, Zhaolin Plaza, No. 19 Ronghua Middle road Beijing Economic and Technological Development Area, Daxing District, Beijing, Beijing China Agenda: To approve Work Report of the Board of Directors for the year 2022; to discuss Work Report of the Supervisory Committee for the year 2022; to discuss Financial Statements for the year 2022; to discuss 2022 Annual Report's full text and report summary and 2022 Annual Results Announcement; to discuss Remuneration of the Directors for the year 2023; to discuss Remuneration of the Supervisors for the year 2023; and to discuss other matters.お知らせ • Jan 31Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2022Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2022. For the period, the company expects the revenue in the range of CNY 10,123.5268 million to CNY 10,346.8399 million. Growth compared with the same period of last year is 36% - 39%. Net profit attributable to owners of the parent is expected to be in the range of CNY 1,312.2126 million to CNY 1,445.0949 million. Growth compared with the same period of last year of -21% to -13%. Basic earnings per share is expected to be in the range of CNY 1.1096 to 1.2220.お知らせ • Nov 07Pharmaron Beijing Co., Ltd. Announces Board ChangesPharmaron Beijing Co., Ltd. announces that Mr. Liu Jun will, due to other work commitments, resign as supervisor of the Company with effect from the date of the extraordinary general meeting of the Company to be convened to approve, among others, the proposed appointment of Supervisor and Ms. Feng Shu has been nominated as candidate for appointment as Supervisor subject to the approval by the shareholders of the Company at the EGM.お知らせ • Oct 15Pharmaron Beijing Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2020 results on Oct 28, 2020お知らせ • Aug 11Pharmaron Beijing Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020Pharmaron Beijing Co., Ltd. announced that they will report first half, 2020 results on Aug 27, 2020株主還元17Q1DE Life SciencesDE 市場7D8.1%1.4%0.2%1Y32.2%6.7%3.6%株主還元を見る業界別リターン: 17Q1過去 1 年間で6.7 % の収益を上げたGerman Life Sciences業界を上回りました。リターン対市場: 17Q1過去 1 年間で3.6 % の収益を上げたGerman市場を上回りました。価格変動Is 17Q1's price volatile compared to industry and market?17Q1 volatility17Q1 Average Weekly Movement8.6%Life Sciences Industry Average Movement6.0%Market Average Movement5.2%10% most volatile stocks in DE Market13.0%10% least volatile stocks in DE Market2.7%安定した株価: 17Q1の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 17Q1の weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200425,088Boliang Louwww.pharmaron.comファーマロン北京有限公司（Pharmaron Beijing Co., Ltd.）は、その子会社とともに、北米、欧州、日本、中国本土、および国際的なライフサイエンス業界に医薬品の研究開発および製造サービスを提供している。同社は、医薬品化学、合成化学、新規モダリティ向け化学、放射性同位元素合成、分析化学、精製化学、DNAコード化ライブラリー、ケムインフォマティクス、コンピューター支援薬物設計などのラボ化学サービス、構造生物学、in vitro生物学、DMPK、in vivo薬理学、化合物管理サービスなどのバイオサイエンスサービス、化学、製造、管理サービスを提供している。また、統合無線標識科学、臨床開発、臨床試験募集サービスを含む臨床開発サービス、安全性評価、統合創薬、バイオアナリシスサービス、生物製剤ラボ、生物製剤CDMO、細胞・遺伝子治療ラボ、遺伝子治療CDMOサービスを含む生物製剤および細胞・遺伝子治療サービスも提供している。ファーマロン北京社は2004年に設立され、中華人民共和国の北京に本社を置いています。もっと見るPharmaron Beijing Co., Ltd. 基礎のまとめPharmaron Beijing の収益と売上を時価総額と比較するとどうか。17Q1 基礎統計学時価総額€10.48b収益（TTM）€217.15m売上高(TTM)€1.87b53.2xPER（株価収益率6.2xP/Sレシオ17Q1 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計17Q1 損益計算書（TTM）収益CN¥14.57b売上原価CN¥9.56b売上総利益CN¥5.01bその他の費用CN¥3.32b収益CN¥1.69b直近の収益報告Mar 31, 2026次回決算日Aug 20, 2026一株当たり利益（EPS）0.92グロス・マージン34.38%純利益率11.62%有利子負債／自己資本比率39.2%17Q1 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.4%現在の配当利回り21%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/16 16:37終値2026/08/14 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharmaron Beijing Co., Ltd. 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22 アナリスト機関Bo LiBofA Global ResearchPei ChengChina Galaxy Securities Co., Ltd.Jin ZhangChina International Capital Corporation Limited19 その他のアナリストを表示
お知らせ • Jun 30Pharmaron Beijing Co., Ltd. to Report First Half, 2026 Results on Aug 21, 2026Pharmaron Beijing Co., Ltd. announced that they will report first half, 2026 results on Aug 21, 2026
お知らせ • Jun 16Pharmaron Beijing Co., Ltd. Approves Cash Dividend for 2025Pharmaron Beijing Co., Ltd. at its AGM held on June 12, 2026, approved cash dividend of CNY 2.00000000 per 10 shares (tax included) for 2025.
お知らせ • May 22Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026, at 13:30 China Standard Time. Location: juhui hall, 5/floor, block b, zhaolin plaza, no. 19 ronghua middle road, beijing economic & technological development area, daxing district, beijing., China
お知らせ • Apr 30Pharmaron Beijing Co., Ltd. Approves Changes in the Company's Accounting PoliciesThe board of directors of Pharmaron Beijing Co., Ltd. that the Board has resolved and approved the proposed changes in the Company's accounting policies. This announcement is made pursuant to the requirements of Rule 13.09(2) of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571). On April 28, 2026, the audit committee of the Board (the "Audit Committee") reviewed and approved the Changes in Accounting Policies, the details of which are as follows: Overview of Changes in Accounting Policies (i) Nature, reasons and effective date of the Changes in Accounting Policies In December, 2025, the Ministry of Finance issued the Notice on the Issuance of Interpretation No. 19 of Accounting Standards for Business Enterprises (Cai Kuai [2025] No. 32) (hereinafter referred to as "Interpretation No. 19"), which stipulates the accounting treatments regarding (i) accounting treatment of indemnification assets in business combinations under non-common control, (ii) accounting treatment of disposing of capital reserve related to the acquisition of subsidiaries through business combinations under common control, (iii) derecognition of financial liabilities settled through electronic payment systems, (iv) assessment of contractual cash flow characteristics of financial assets and related disclosures, and (v) disclosures of equity instruments designated as measured at fair value through other comprehensive income. The Interpretation No. 19 shall take effect from January 1, 2026. In accordance with the Interpretation No. 19, the Company has adopted the above accounting standards for business enterprises and the related accounting policies commencing from the effective date specified therein. These Changes in Accounting Policies are made in accordance with the requirements of the unified national accounting system. (ii) Accounting policies adopted prior to the Changes in Accounting Policies Prior to the Changes in Accounting Policies, the Company adopted the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations issued by the Ministry of Finance. (iii) Accounting policies adopted after the Changes in Accounting Policies After the Changes in Accounting Policies, the Company will adopt the requirements of Interpretation No. 19. The unchanged remaining parts will continue to follow the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, the Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations previously issued by the Ministry of Finance. II. Impacts of Changes in Accounting Policies on the Company These Changes in Accounting Policies are made by the Company in accordance with the relevant regulations and requirements of the Ministry of Finance, and are in compliance with relevant laws and regulations. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years, will have no material effect on the Company's financial position, operating results or cash flows, and do not prejudice the interests of the Company and all of its shareholders. The Change in Accounting Policies is a modification under the China Accounting Standards, and will not have any impact on the Company's audited consolidated financial statements prepared in accordance with IFRS Accounting Standards (which include all International Financial Reporting Standards, International Accounting Standards and Interpretations) as issued by the International Accounting Standards Board. III. Opinion of the Audit Committee of the Board The Audit Committee is of the opinion that the Changes in Accounting Policies are made by the Company in compliance with the requirements of the relevant documents issued by the Ministry of Finance and constitute changes in accounting policies as required by the unified national accounting system. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years and do not prejudice the interests of the Company and all of its shareholders. The Audit Committee unanimously approved the Changes in Accounting Policies. In accordance with the Rules Governing the Listing of Stocks on the ChiNext Board of the Shenzhen Stock Exchange and other applicable laws, regulations and departmental rules, the Changes in Accounting Policies are not required to be submitted to the Board or the 2025 AGM for approval.
お知らせ • Apr 29Pharmaron Beijing Co., Ltd. Announces Board ResignationsPharmaron Beijing Co., Ltd. announced that Mr. LI Jiaqing and Mr. YU Jian will not stand for re-election of the fourth session of the Board. Each of Mr. LI Jiaqing and Mr. YU Jian has confirmed that he has no disagreement with the Board and there is no matter that need to be brought to the attention of the Shareholders with regard to his resignation. As at the date of this announcement, neither Mr. LI Jiaqing nor Mr. YU Jian has any interest in the shares of the Company within the meaning of Part XV of the SFO nor any other matter which needs to be brought to the attention of the Shareholders. The Board would like to take this opportunity to express its appreciation and gratitude to Mr. LI Jiaqing and Mr. YU Jian for their valuable contribution made to the Company during their respective term of service.
お知らせ • Mar 31Pharmaron Beijing Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
お知らせ • Jun 30Pharmaron Beijing Co., Ltd. to Report First Half, 2026 Results on Aug 21, 2026Pharmaron Beijing Co., Ltd. announced that they will report first half, 2026 results on Aug 21, 2026
お知らせ • Jun 16Pharmaron Beijing Co., Ltd. Approves Cash Dividend for 2025Pharmaron Beijing Co., Ltd. at its AGM held on June 12, 2026, approved cash dividend of CNY 2.00000000 per 10 shares (tax included) for 2025.
お知らせ • May 22Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 12, 2026, at 13:30 China Standard Time. Location: juhui hall, 5/floor, block b, zhaolin plaza, no. 19 ronghua middle road, beijing economic & technological development area, daxing district, beijing., China
お知らせ • Apr 30Pharmaron Beijing Co., Ltd. Approves Changes in the Company's Accounting PoliciesThe board of directors of Pharmaron Beijing Co., Ltd. that the Board has resolved and approved the proposed changes in the Company's accounting policies. This announcement is made pursuant to the requirements of Rule 13.09(2) of the Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571). On April 28, 2026, the audit committee of the Board (the "Audit Committee") reviewed and approved the Changes in Accounting Policies, the details of which are as follows: Overview of Changes in Accounting Policies (i) Nature, reasons and effective date of the Changes in Accounting Policies In December, 2025, the Ministry of Finance issued the Notice on the Issuance of Interpretation No. 19 of Accounting Standards for Business Enterprises (Cai Kuai [2025] No. 32) (hereinafter referred to as "Interpretation No. 19"), which stipulates the accounting treatments regarding (i) accounting treatment of indemnification assets in business combinations under non-common control, (ii) accounting treatment of disposing of capital reserve related to the acquisition of subsidiaries through business combinations under common control, (iii) derecognition of financial liabilities settled through electronic payment systems, (iv) assessment of contractual cash flow characteristics of financial assets and related disclosures, and (v) disclosures of equity instruments designated as measured at fair value through other comprehensive income. The Interpretation No. 19 shall take effect from January 1, 2026. In accordance with the Interpretation No. 19, the Company has adopted the above accounting standards for business enterprises and the related accounting policies commencing from the effective date specified therein. These Changes in Accounting Policies are made in accordance with the requirements of the unified national accounting system. (ii) Accounting policies adopted prior to the Changes in Accounting Policies Prior to the Changes in Accounting Policies, the Company adopted the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations issued by the Ministry of Finance. (iii) Accounting policies adopted after the Changes in Accounting Policies After the Changes in Accounting Policies, the Company will adopt the requirements of Interpretation No. 19. The unchanged remaining parts will continue to follow the Accounting Standards for Business Enterprises Basic Standards and various specific accounting standards, the Application Guidelines for Accounting Standards for Business Enterprises, the interpretation announcements of the Accounting Standards for Business Enterprises and other relevant regulations previously issued by the Ministry of Finance. II. Impacts of Changes in Accounting Policies on the Company These Changes in Accounting Policies are made by the Company in accordance with the relevant regulations and requirements of the Ministry of Finance, and are in compliance with relevant laws and regulations. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years, will have no material effect on the Company's financial position, operating results or cash flows, and do not prejudice the interests of the Company and all of its shareholders. The Change in Accounting Policies is a modification under the China Accounting Standards, and will not have any impact on the Company's audited consolidated financial statements prepared in accordance with IFRS Accounting Standards (which include all International Financial Reporting Standards, International Accounting Standards and Interpretations) as issued by the International Accounting Standards Board. III. Opinion of the Audit Committee of the Board The Audit Committee is of the opinion that the Changes in Accounting Policies are made by the Company in compliance with the requirements of the relevant documents issued by the Ministry of Finance and constitute changes in accounting policies as required by the unified national accounting system. The revised accounting policies objectively and fairly reflect the Company's financial position and operating results. The Changes in Accounting Policies do not involve retroactive adjustment of financial data for previous years and do not prejudice the interests of the Company and all of its shareholders. The Audit Committee unanimously approved the Changes in Accounting Policies. In accordance with the Rules Governing the Listing of Stocks on the ChiNext Board of the Shenzhen Stock Exchange and other applicable laws, regulations and departmental rules, the Changes in Accounting Policies are not required to be submitted to the Board or the 2025 AGM for approval.
お知らせ • Apr 29Pharmaron Beijing Co., Ltd. Announces Board ResignationsPharmaron Beijing Co., Ltd. announced that Mr. LI Jiaqing and Mr. YU Jian will not stand for re-election of the fourth session of the Board. Each of Mr. LI Jiaqing and Mr. YU Jian has confirmed that he has no disagreement with the Board and there is no matter that need to be brought to the attention of the Shareholders with regard to his resignation. As at the date of this announcement, neither Mr. LI Jiaqing nor Mr. YU Jian has any interest in the shares of the Company within the meaning of Part XV of the SFO nor any other matter which needs to be brought to the attention of the Shareholders. The Board would like to take this opportunity to express its appreciation and gratitude to Mr. LI Jiaqing and Mr. YU Jian for their valuable contribution made to the Company during their respective term of service.
お知らせ • Mar 31Pharmaron Beijing Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
お知らせ • Jan 22Pharmaron Beijing Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.333618 billion.Pharmaron Beijing Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 1.333618 billion. Security Name: H shares Security Type: Common Stock Securities Offered: 58,440,762 Price\Range: HKD 22.82 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 15Pharmaron Beijing Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 1.333618 billion.Pharmaron Beijing Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 1.333618 billion. Security Name: H shares Security Type: Common Stock Securities Offered: 58,440,762 Price\Range: HKD 22.82 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 14Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2025Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2025. For the period, the company expects the revenue in the range of RMB 13,871.6256 million to RMB 14,239.8989 million, growth compared with the same period of last year is 13% - 16%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,614.0157 million to RMB 1,685.7498 million, decrease compared with the same period of last year of 6% to 10%. Basic earnings per share is expected to be in the range of RMB 0.0.9160 to RMB 0.9567.
お知らせ • Dec 31Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026
お知らせ • Oct 29Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into a definitive Share Purchase Agreement to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd.Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into a definitive Share Purchase Agreement to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd. on October 28, 2025. With this transaction, it will further enhance its service capabilities in protein science, biological assaying and compound screening, protein crystallization and structure analysis and structure-based drug design. The transaction is expected to close upon the satisfaction of customary closing conditions.
お知らせ • Sep 30Pharmaron Beijing Co., Ltd. to Report Q3, 2025 Results on Oct 29, 2025Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025
お知らせ • Jul 02Pharmaron Beijing Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025Pharmaron Beijing Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
お知らせ • Jun 20Pharmaron Beijing Co., Ltd. Approves Final Ordinary Dividend for Year Ended December 31, 2024, Payment Date Is 06 August 2025Pharmaron Beijing Co., Ltd. approved final ordinary dividend in cash for the year ended December 31, 2024 of RMB 2 per 10 share. Ex-dividend date is 04 July 2025 . Record date is 14 July 2025. Payment date is 06 August 2025. Date of shareholders' approval is 20 June 2025.
お知らせ • May 29Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 20, 2025Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 20, 2025, at 13:30 China Standard Time. Location: no. 1 meeting room,4th floor, grand skylight international hotel beijing, building 10, avic plaza, no. 15 ronghua south road, yizhuang economic and technological development, zone, daxing China
お知らせ • Apr 28Pharmaron Beijing Co., Ltd. Announces Resignation of Hu Baifeng as Non-Executive Director and A Member of the Strategy CommitteePharmaron Beijing Co., Ltd. announced that Mr. Hu Baifeng (Mr. Hu) has tendered a voluntary resignation from his position as a non-executive Director of the Company and a member of the strategy committee of the Board (the Strategy Committee). Following Mr. Hu's resignation, he has voluntarily agreed to continue to perform his duties as a non-executive Director and a member of the Strategy Committee until the proposed election of the new non-executive Director is resolved by the shareholders of the Company (the Shareholders) at the upcoming annual general meeting of the Company for the year 2024 (the 2024 AGM).
お知らせ • Mar 31Pharmaron Beijing Co., Ltd. to Report Q1, 2025 Results on Apr 28, 2025Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2025 results on Apr 28, 2025
お知らせ • Mar 26Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2024Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2024.
お知らせ • Dec 31Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2024 Results on Mar 27, 2025Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2024 results on Mar 27, 2025
お知らせ • Sep 30Pharmaron Beijing Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024
お知らせ • Jun 29Pharmaron Beijing Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Pharmaron Beijing Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024
お知らせ • Jun 22Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million and with potential for an additional milestone payment. on May 16, 2024. The transaction is subject to antitrust clearance and other customary closing conditions. The transaction is expected to close mid-year 2024. Centerview Partners LLC served as exclusive financial advisor, and Goodwin Procter as legal counsel to Proteologix on the transaction. The transaction has been approved by Pharmaron Beijing Co., Ltd's board.As of year ended 2023, Proteologix, Inc reported total assets of $31.04 million, total common equity of $30.73 million, EBIT of $5.74 million and net income of $5.74 million. Janet Xiao of Morrison & Foerster LLP acted as legal advisor to Proteologix, Inc.Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders on June 21, 2024.
お知らせ • Jun 21Pharmaron Beijing Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable June 27, 2024Pharmaron Beijing Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 2.00000000 on A shares for the year 2023. Record date is June 26, 2024. Ex-date is June 27, 2023. Payment date is June 27, 2024.
お知らせ • Jun 08Pharmaron Beijing Co., Ltd. Approves Final Dividend for the Financial Year Ended December 31, 2023, Payable on July 26, 2024Pharmaron Beijing Co., Ltd. approved final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023. Ex-dividend date is on 27 June 2024. Record date is on 08 July 2024. Payment date is on 26 July 2024. Date of shareholders' approval is on 6 June 2024.
お知らせ • May 16Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 06, 2024, at 13:30 China Standard Time. Location: paris hall, 3/f, pullman beijing south, no. 12 ronghua south road, beijing economic and technological development, area, daxing district, beijing China
お知らせ • Apr 26+ 1 more updatePharmaron Beijing Co., Ltd. (SZSE:300759) announces an Equity Buyback for CNY 300 million worth of its shares.Pharmaron Beijing Co., Ltd. (SZSE:300759) announces a share repurchase program. Under the program, the company will repurchase up to CNY 300 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 31 per share. The A Shares repurchased will all be cancelled and the Company’s registered capital will be reduced accordingly. The purpose of the program is to enhance investor’s confidence, and comprehensively taking into account the Company’s financial conditions, future development and reasonable valuation levels. The program will be funded out of the company's own funds. The program will be valid till 3 months.
お知らせ • Mar 30Pharmaron Beijing Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Pharmaron Beijing Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
お知らせ • Mar 27Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. proposed final dividend of RMB 2 per 10 shares for the financial year ended December 31, 2023.
お知らせ • Jan 29Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2023. For the period, the company expects the revenue in the range of RMB 11,395.5799 million to RMB 11,703.5685 million. Growth compared with the same period of last year is 11% - 14%. Net profit attributable to owners of the parent is expected to be in the range of RMB 1,567.0488 million to RMB 1,635.7790 million. Growth compared with the same period of last year of 14% to 19%. Basic earnings per share is expected to be in the range of RMB 0.8841 to 0.9229.
お知らせ • Dec 29Pharmaron Beijing Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024Pharmaron Beijing Co., Ltd. announced that they will report fiscal year 2023 results on Mar 28, 2024
お知らせ • Jul 23Pharmaron Beijing Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 27, 2023Pharmaron Beijing Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 26, 2023. Ex-date is July 27, 2023. Payment date is July 27, 2023.
お知らせ • Jun 27Pharmaron Beijing Co., Ltd. Approves Cash Dividend for 2022Pharmaron Beijing Co., Ltd. approved Cash dividend/10 shares (tax included) of CNY 3.00000000 for 2022 at the Class Meeting of Holders of Domestic Shares of 2023 held on June 21, 2023.
お知らせ • May 26+ 1 more updatePharmaron Beijing Co., Ltd., Annual General Meeting, Jun 21, 2023Pharmaron Beijing Co., Ltd., Annual General Meeting, Jun 21, 2023, at 13:30 China Standard Time. Location: Juyuan Hall, 5/F, Block A, Zhaolin Plaza, No. 19 Ronghua Middle road Beijing Economic and Technological Development Area, Daxing District, Beijing, Beijing China Agenda: To approve Work Report of the Board of Directors for the year 2022; to discuss Work Report of the Supervisory Committee for the year 2022; to discuss Financial Statements for the year 2022; to discuss 2022 Annual Report's full text and report summary and 2022 Annual Results Announcement; to discuss Remuneration of the Directors for the year 2023; to discuss Remuneration of the Supervisors for the year 2023; and to discuss other matters.
お知らせ • Jan 31Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2022Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2022. For the period, the company expects the revenue in the range of CNY 10,123.5268 million to CNY 10,346.8399 million. Growth compared with the same period of last year is 36% - 39%. Net profit attributable to owners of the parent is expected to be in the range of CNY 1,312.2126 million to CNY 1,445.0949 million. Growth compared with the same period of last year of -21% to -13%. Basic earnings per share is expected to be in the range of CNY 1.1096 to 1.2220.
お知らせ • Nov 07Pharmaron Beijing Co., Ltd. Announces Board ChangesPharmaron Beijing Co., Ltd. announces that Mr. Liu Jun will, due to other work commitments, resign as supervisor of the Company with effect from the date of the extraordinary general meeting of the Company to be convened to approve, among others, the proposed appointment of Supervisor and Ms. Feng Shu has been nominated as candidate for appointment as Supervisor subject to the approval by the shareholders of the Company at the EGM.
お知らせ • Oct 15Pharmaron Beijing Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020Pharmaron Beijing Co., Ltd. announced that they will report Q3, 2020 results on Oct 28, 2020
お知らせ • Aug 11Pharmaron Beijing Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020Pharmaron Beijing Co., Ltd. announced that they will report first half, 2020 results on Aug 27, 2020
